A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury

Toxicology Letters

Volumn 241, Issue , 2016, Pages 60-70

  Oda, Shingo ^a   Matsuo, Kentaro ^b   Nakajima, Akira ^a   Yokoi, Tsuyoshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cell based assay; Drug metabolism; Drug induced liver injury; Immune reaction

Indexed keywords

ABACAVIR; ACARBOSE; ALPIDEM; AMIODARONE; BENOXAPROFEN; BENZBROMARONE; BICALUTAMIDE; BIOLOGICAL MARKER; BROMFENAC; CALGRANULIN B; CARBAMAZEPINE; CIPROFLOXACIN; DANAZOL; DICLOFENAC; ERYTHROMYCIN; ETODOLAC; FELBAMATE; FENOPROFEN; FLUTAMIDE; IBUFENAC; INTERLEUKIN 1BETA; INTERLEUKIN 8; IPRONIAZID; ISONIAZID; KETOCONAZOLE; LUMIRACOXIB; MESSENGER RNA; METHOTREXATE; THIAMAZOLE; UNINDEXED DRUG; CONDITIONED MEDIUM;

AREA UNDER THE CURVE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG METABOLISM; DRUG SAFETY; GENE EXPRESSION; GENE FUNCTION; HEPATOMA CELL; HEPG2 CELL LINE; HL 60 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPENSITY SCORE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; BIOSYNTHESIS; CELL SURVIVAL; CHEMICALLY INDUCED; CONDITIONED MEDIUM; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLIC ACTIVATION; PATHOLOGY; TUMOR CELL LINE;

ACTIVATION, METABOLIC; AREA UNDER CURVE; BIOMARKERS; CALGRANULIN B; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION; HL-60 CELLS; HUMANS; INFLAMMATION; RISK ASSESSMENT; ROC CURVE;

EID: 84947983542     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.10.029     Document Type: Article

References (48)

1. Adams D.H., Ju C., Ramaiah S.K., Uetrecht J., Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 2010, 115:307-321.
2. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34:75-83.
3. Bova M.P., Tam D., McMahon G., Mattson M.N. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol. Lett. 2005, 155:41-50.
4. Chen C.J., Kono H., Golenbock D., Reed G., Akira S., Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007, 13:851-856.
5. Chen M., Vijay V., Shi Q., Liu Z., Fang H., Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 2011, 16:697-703.
6. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., Griffith L.G., Sorger P.K., Tidor B., Xu J.J., Lauffenburger D.A. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 2009, 237:317-330.
7. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
8. Feng D., Wang Y., Xu Y., Luo Q., Lan B., Xu L. Interleukin 10 deficiency exacerbates halothane induced liver injury by increasing interleukin 8 expression and neutrophil infiltration. Biochem. Pharmacol. 2009, 77:277-284.
9. Fujimoto K., Kumagai K., Ito K., Arakawa S., Ando Y., Oda S., Yamoto T., Manabe S. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol. Pathol. 2009, 37:193-200.
10. Gerets H.H., Tilmant K., Gerin B., Chanteux H., Depelchin B.O., Dhalluin S., Atienzar F.A. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 2012, 28:69-87.
11. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8:E101-E111.
12. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
13. Holt M.P., Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006, 8:E48-E54.
14. Hosomi H., Fukami T., Iwamura A., Nakajima M., Yokoi T. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab. Dispos. 2011, 39:1388-1395.
15. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., Flavell R.A., Mehal W.Z. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 2009, 119:305-314.
16. Iwamura A., Fukami T., Hosomi H., Nakajima M., Yokoi T. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab. Dispos. 2011, 39:838-846.
17. Jaeschke H. Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Exp. Opin. Drug Metab. Toxicol. 2005, 1:389-397.
18. Josse R., Aninat C., Glaise D., Dumont J., Fessard V., Morel F., Poul J.M., Guguen-Guillouzo C., Guillouzo A. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab. Dispos. 2008, 36:1111-1118.
19. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4:489-499.
20. Khetani S.R., Kanchagar C., Ukairo O., Krzyzewski S., Moore A., Shi J., Aoyama S., Aleo M., Will Y. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol. Sci. 2013, 132:107-117.
21. Kon K., Kim J.S., Jaeschke H., Lemasters J.J. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004, 40:1170-1179.
22. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis. 2002, 22:145-156.
23. Laskin D.L., Laskin J.D. Role of macrophages and inflammatory mediators in chemically induced toxicity. Toxicology 2001, 160:111-118.
24. Lee W.M. Drug-induced acute liver failure. Clin. Liver Dis. 2013, 17:575-586. viii.
25. Liaskou E., Wilson D.V., Oo Y.H. Innate immune cells in liver inflammation. Mediators Inflamm. 2012, 2012. 949157.
26. Liu Z.X., Govindarajan S., Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004, 127:1760-1774.
27. Martin-Murphy B.V., Holt M.P., Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. Toxicol. Lett. 2010, 192:387-394.
28. Masson M.J., Carpenter L.D., Graf M.L., Pohl L.R. Pathogenic role of natural killer T and natural killer cells in acetaminophen-induced liver injury in mice is dependent on the presence of dimethyl sulfoxide. Hepatology 2008, 48:889-897.
29. Masubuchi Y., Kano S., Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006, 222:233-239.
30. Mizuno K., Toyoda Y., Fukami T., Nakajima M., Yokoi T. Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch. Toxicol. 2011, 85:199-207.
31. McGill M.R., Yan H.M., Ramachandran A., Murray G.J., Rollins D.E., Jaeschke H. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 2011, 53:974-982.
32. Mueller D., Kramer L., Hoffmann E., Klein S., Noor F. 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicol. In Vitro 2014, 28:104-112.
33. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
34. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
35. Park B.K., Kitteringham N.R., Maggs J.L., Pirmohamed M., Williams D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 2005, 45:177-202.
36. Ponsoda X., Bort R., Jover R., Gomez-Lechon M.J., Castell J.V. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem. Pharmacol. 1999, 58:1579-1585.
37. Singer J.B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., Wright T.M., Meyer J., Paulding C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42:711-714.
38. Stepan A.F., Walker D.P., Bauman J., Price D.A., Baillie T.A., Kalgutkar A.S., Aleo M.D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 2011, 24:1345-1410.
39. Steuerwald N.M., Foureau D.M., Norton H.J., Zhou J., Parsons J.C., Chalasani N., Fontana R.J., Watkins P.B., Lee W.M., Reddy K.R., Stolz A., Talwalkar J., Davern T., Saha D., Bell L.N., Barnhart H., Gu J., Serrano J., Bonkovsky H.L. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013, 8:e81974.
40. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 2009, 37:2383-2392.
41. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., Nacken W., Foell D., van der Poll T., Sorg C., Roth J. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 2007, 13:1042-1049.
42. Wang G., Siow Y.L., O K. Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-kappaB in THP-1 macrophages. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H2840-H2847.
43. Wilkening S., Stahl F., Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 2003, 31:1035-1042.
44. Wink S., Hiemstra S., Huppelschoten S., Danen E., Niemeijer M., Hendriks G., Vrieling H., Herpers B., van de Water B. Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem. Res. Toxicol. 2014, 27:338-355.
45. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
46. Yano A., Oda S., Fukami T., Nakajima M., Yokoi T. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol. Lett. 2014, 228:13-24.
47. You Q., Cheng L., Reilly T.P., Wegmann D., Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006, 44:1421-1431.
48. Yuan L., Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol. Asp. Med. 2009, 30:29-41.